Status:
COMPLETED
A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Non-Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This 3 arm study will compare the efficacy and safety of three different dermatological creams designed for prophylaxis of skin rash associated with Tarceva treatment in patients with locally advanced...
Eligibility Criteria
Inclusion
- adult patients, \>=18 years of age;
- locally advanced or metastatic non-small cell lung cancer (stage IIIB/IV);
- eligible to start treatment with Tarceva, or receiving Tarceva for \<=5 days.
Exclusion
- presence of skin rash or other signs of skin toxicity;
- treatment with any systemic or intranasal antibiotic within 7 days before randomization;
- treatment with other topical formulation within 14 days before randomization;
- other anticancer therapy in addition to Tarceva.
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2012
Estimated Enrollment :
201 Patients enrolled
Trial Details
Trial ID
NCT00718315
Start Date
April 1 2009
End Date
June 1 2012
Last Update
January 15 2015
Active Locations (26)
Enter a location and click search to find clinical trials sorted by distance.
1
Fortaleza, Ceará, Brazil, 60125-151
2
Fortaleza, Ceará, Brazil, 60190-800
3
Salvador, Estado de Bahia, Brazil, 40110-150
4
Salvador, Estado de Bahia, Brazil, 40170-110